As Seeger and Choi have pointed out, pravastatin does not share the in vitro effect of other statins on bone morphogenetic protein-2 production.1 Subgroup analysis of data from the Geelong Osteoporosis Study2 for pravastatin alone was not performed because the subsample size was too small for statistical analysis. From a group of 69 statin users, 10 used pravastatin (3 from the fracture group and 7 from the nonfracture group). However, the original data set has been reanalyzed with pravastatin users excluded, and results are presented in Table 1.
Pasco JA, Kotowicz MA, Henry MJ, Sanders KM, Nicholson GC. Statin Use and Fracture Risk—Reply. Arch Intern Med. 2002;162(20):2379-2380. doi: